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Abstract
Background: ATP-binding cassette transporter abcc2 is involved in the cellular efflux of irinotecan. The drug is toxic for
mouse ileum, where abcc2 is highly expressed. Here, we investigate whether circadian changes in local abcc2 expression
participate in the circadian rhythm of irinotecan toxicity for ileum mucosa, and further assess whether genetic background
or sex modify this relation.
Methodology/Principal Findings: Ileum mucosa was obtained every 3–4 h for 24 h in male and female B6D2F1 and
B6CBAF1 mice synchronized with light from Zeitgeber Time (ZT)0 to ZT12 alternating with 12 h of darkness. Irinotecan
(50 mg/kg i.v. daily for 4 days) was administered at the sex- and strain-specific times corresponding to least (ZT11-15) or
largest drug-induced body weight loss (ZT23-03-07). Abcc2 expression was determined with qRT-PCR for mRNA and with
immunohistochemistry and confocal microscopy for protein. Histopathologic lesions were graded in ileum tissues obtained
2, 4 or 6 days after treatment. Two- to six-fold circadian changes were demonstrated for mRNA and protein mean
expressions of abcc2 in mouse ileum (p,0.05). ZT12 corresponded to high mRNA and protein expressions, with circadian
waveforms differing according to genetic background and sex. The proportion of mice spared from ileum lesions varied
three-fold according to irinotecan timing, with best tolerability at ZT11-15 (p=0.00003). Irinotecan was also best tolerated in
males (p=0.05) and in B6CBAF1 (p=0.0006).
Conclusions/Significance: Strain- and sex-dependent circadian patterns in abcc2 expressions displayed robust relations
with the chronotolerance of ileum mucosa for irinotecan. This finding has strong potential implications for improving the
intestinal tolerability of anticancer drugs through circadian delivery.
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Introduction
Molecular circadian clocks rhythmically control Phase I and II
metabolism over the 24 hours in mammals [1–3]. The molecular
clocks in each cell are coordinated through an array of
physiological rhythms generated by the suprachiasmatic nuclei
(SCN) in the hypothalamus. Such circadian timing system
determines rhythmic changes in drugs effects [3]. This is
particularly relevant for anticancer drugs, with a narrow
therapeutic index. Indeed, circadian timing modifies 2- to 10-
times the extent of toxic effects of 40 anticancer medications in
rodents, and up to 5-fold that of 5-fluorouracil-oxaliplatin in
cancer patients [4–6]. The mechanisms of drug detoxification
involve the cellular efflux of medications and/or their metabolites
via specific transporters. However the possible relevance of a
circadian regulation of drug transporters for anticancer drug
tolerability has not been addressed yet.
Many anticancer drugs and/or their metabolites are expelled
out of cells by ATP-binding cassette (ABC) transporter proteins
which function as ATP-dependent molecule pumps in the cell
membrane. ABCC2 (human)/abcc2 (rodent) is one such ABC
transporter also known as multidrug resistance-associated protein-
2 (MRP2/mrp2) or canalicular multispecific organic anion
transporter (cMOAT).
ABCC2/abcc2 overexpression confers multidrug resistance
(MDR) to colon, breast, lung or renal cell carcinomas [7,8].
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20393ABCC2/abcc2 is also expressed in healthy tissues, where it could
influence the toxic effects of anticancer agents, especially for the
gastrointestinal tract. The highest mRNA expression of abcc2 was
found in liver for rats and humans, and in small intestine for mice,
with a decreasing gradient from duodenum to ileum [9–11].
Lowest expression was found in mouse colon [10]. Abcc2 protein
expression in rat ileum was localized in the brush-border
membrane, and with highest values in the apical part of the villus
rather than in the crypt [12].
The gut toxicities of irinotecan (7-ethyl-10-[4-(1-piperidino)-1-
piperidino]-carbonyloxycamptothecin) limit the use of this effec-
tive drug against gastro-intestinal malignancies [13]. Large and
consistent circadian changes in irinotecan toxicities were found in
mice whose circadian timing system was synchronized with an
alternation of 12 h of light from ZT0 to ZT12 (zeitgeber time) and
darkness from ZT12 to ZT24/0. Best tolerability corresponded to
drug dosing between ZT7 and ZT15 according to strain, sex and
experimental conditions [14,15]. In an initial study in male
B6D2F1, severe ileum mucosa lesions were identified in mice
receiving irinotecan at ZT19 to ZT3, but not in those treated at
ZT7 to ZT15. Thus, best ileum tolerability corresponded to
irinotecan dosing between mid-rest and early activity span [15]. In
subsequent investigation, irinotecan toxicity at ZT7 was least in
female as compared with male mice, and varied significantly
according to mouse strain. Furthermore, both genetic background
and sex significantly altered the molecular prediction of irinotecan
toxicity by the mRNA expression of enzymes involved in drug
bioactivation, such as carboxylesterase 2 (ces2), detoxification, such
as UDP-glucuronosyltransferase (ugt1a1), and DNA replication,
such as topoisomerase 1 (top1) [16].
Irinotecan detoxification also involves its cellular efflux through
abcc2 [17]. This transporter is known to display circadian changes
in liver and intestine [18,19]. Here, we specifically investigated the
relations between abcc2 expression and irinotecan toxicity in
mouse ileum. Circadian rhythms are shown at mRNA and protein
expression levels through quantitative RT-PCR and confocal
immunohistochemistry respectively. These results are qualified
with regard to villus localization, strain and sex.
The study is the first one to demonstrate that abcc2 mRNA and
protein expressions are regulated along the 24 h in mouse ileum
mucosa. Circadian rhythm in abcc2 expression contributes to that
in irinotecan tolerability. We further discuss its relevance for
tolerability pattern of other anticancer drug effluxed by abcc2 as
well.
Materials and Methods
Animals and synchronization
The study was conducted in accordance with the guidelines
approved for animal experimental procedures by the French
Ethical Committee (decree 87–848). All the experiments involved
male and female B6D2F1 or B6CBAF1 mice 7 weeks of age
purchased from Janvier (Le Genest St Isle, France). They were
synchronized with an alternation of 12 h of light and 12 h of
darkness (LD12:12) in an autonomous chronobiological facility
(Jouan-Thermo Electron LED S.A.S., Saint-Herblain, France)
with food and water ad libitum for 3 weeks prior to any
intervention. Each facility is equipped with temperature control
(2361uC) and comprises four or six compartments, each one being
provided with separate filtered air (100610 l/min) and lighting
regimen. Light intensity at cage level ranged from 223 to 315 lux.
All the manipulations during the dark phase were performed
under dim red light (7 lux).
Experimental design
Circadian rhythms in the mRNA expression of abcc2 were first
investigated separately in ileum serosa and in scraped ileum
mucosa of 30 male B6D2F1 mice sampled at one of six ZT
equispaced by 4 h (Study 1). Time (in hours) was referred to ZT0
(light onset).
In order to enhance temporal resolution, subsequent experi-
ments involved sampling of scraped ileum mucosa at one of eight
ZT separated by 3 h, in 40 male and 40 female B6D2F1
(RC57BL/66=DBA/2), or 40 male and 40 female B6CBAF1
mice (RC57BL/66=CBA) for the determination of mRNA
expression patterns as a function of ZT, gender and genetic
background (Study 2).
In Study 3, the abcc2 protein localization was assessed using
immunohistochemistry, confocal microscopy and quantification
through image analysis at 4 circadian times associated with high
(ZT12 and ZT15) or low (ZT0 and ZT3) mRNA expressions, as
defined in study 2. Study 3 involved 20 male or female mice of
both strains.
Study 4 tested the hypothesis that ileum toxicity of irinotecan
would differ as a function of circadian timing, genetic background
and sex in a total of 66 mice. Irinotecan was administered at a
circadian time previously shown to determine ‘‘best’’ or ‘‘worst’’
tolerability, based on body weight loss in each mouse group [16].
RNA extraction
Total RNA from liver was purified using the method of
Chomczynski and Sacchi [20] and stored at 280uC until use.
PCR was performed with a LightCycler 480 (Roche, Meylan,
France) using SYBR green I dye detection according to the
manufacturer’s recommendations. cDNA was added to a reaction
mixture (Faststart DNA SYBR Green I; Roche Diagnostics,
Meylan, France) with appropriate primers at 0.5 mM each.
Relative mRNA abundance was calculated using a standard curve
method. Expression levels were normalized to the levels of the
constitutively and non-rhythmically expressed 36B4 (acidic
ribosomal phosphoprotein P0). The following primers were used
for abcc2 accession number: NM-013806.2; forward, 59-GCTGA-
GATCGGAGAGAAGGGTA- 39 and reverse, 59-CACTTGGG-
GAAGGAAGTGAA -39, for 36B4 Accession number:
NM_007475.3; forward 59-GCTGATGGGCAAGAACACCA-39
and reverse 59-CCCAAAGCCTGGAAGAAGGA-39.
Protein expression studies
Mouse ileum was fixed in 4% buffered formalin at room
temperature for 24 h. The fixed tissues were then dehydrated in
ethanol, cleared in Bioclear (Bioptica, Milan, Italy) then embedded
into paraffin. Sections were cut to a thickness of 5 mm and
transferred to positively charged slides. Slides were incubated
overnight at 37uC and immersed in xylol in order to remove
paraffin. Tissue sections were rehydrated in a graded alcohol series
(100%, 96% and 80%) for 5 min in each bath and rinsed in
running tap water. Haematoxylin and Eosin (H&E) staining was
performed according to a routine protocol in order to estimate the
quality of the tissue. Immunohistochemistry analysis was per-
formed using a tissue microarray with cylindrical cores of 2 mm of
paraffin-embedded tissue [21].
Immunohistochemistry and confocal microscopy
A microwave (three times five minutes, at 600 W) method using
citrate buffer (pH=6) was used for antigen retrieval. Sections were
incubated for 60 min at room temperature with Rodent Block M
(Biocare Medical, Concord, CA) and then incubated for 30 min
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anti-mouse abcc2 antibody (LifeSpan Technologies, Seattle, USA)
diluted 1:25 in PBS, or a mouse anti-mouse b-catenin antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:50 in PBS
were then incubated over night at 4uC. After three washes in PBS,
sections were co incubated for 60 min at room temperature with
Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody
or Alexa Fluor 546-conjugated goat anti-mouse from Molecular
Probes (Invitrogen, Milan, Italy) and with the far-red fluorescent
DNA dye DRAQ5 (Alexis, Lausen, Switzerland) to visualize
nuclei. As a negative control, tissues were stained with rabbit IgG
(Jackson Laboratories, Bar Harbor, Maine) at the same concen-
trations used for the primary antibody. Following three brief PBS
washes, samples were mounted using an aqueous mountant, Eukitt
(Bioptica, Milan, Italy).
Image analysis
Images were acquired with the Zeiss LSM 510 meta-confocal
microscope using a 488, 546 and 633-nm lasers. Detector gain
voltages and pinhole were set at the beginning of the experiment
and maintained constant during the acquisition of all samples. For
each tissue section, three images were collected corresponding to
different areas of the section. To provide a quantitative estimate of
abcc2 protein expression, images were analyzed with Image
ProPlus 6.0 software (Media Cybernetics, Bethesda, MD). The
standard version of the software was modified in order to measure
the fluorescent area in an automatic manner (Immagini&Compu-
ter, Milan, Italy). Briefly, at the beginning of the acquisition
analysis, the fluorescence background was subtracted from each
image; then the software estimated the number of nuclei and
measured the fluorescent area. The obtained value was then
divided by the number of nuclei to obtain a mean value of
fluorescence area. To reduce inter-assay variability, mean values
were expressed as a percentage of abcc2 expression in a control
ileum from a BALB/c mouse.
Drug
The clinical solution for intravenous (i.v.) injection of irinotecan
(20 mg/mL; Aventis, Milan, Italy) was diluted in 0.9% sodium
chloride on each study day, prior to injections. The final drug
solution was administered i.v. at the dose of 50 mg/kg into the
right retro-orbital venous sinus once daily for 4 consecutive days
[15,16]. Irinotecan was injected at the ZT corresponding to best
tolerability of irinotecan, i.e. ZT11 in male B6D2F1 and ZT15 in
female B6D2F1 and in male or female B6CBAF1 mice, or to worst
tolerability, i.e. ZT23 in male B6D2F1, ZT3 in female B6D2F1,
and ZT7 in male or female B6CBAF1 according to prior study
[15,16].
Histologic lesions
Ileum toxicities were assessed in 6–8 mice of each group treated
at each ZT two, four and six days after irinotecan treatment.
Sampling was performed at the same ZT as that of drug
administration. Three control animals were also used per sampling
time point and per group. The ileum was obtained immediately
after sacrifice and fixed into 4% formaldehyde. Twenty four hours
later, the samples were dehydrated and embedded into paraffin.
Sections were made and stained with hemalun-erythrosine-safran.
Each slide was examined by the same histopathologist and lesions
were graded in a blind manner. The occurrence of ileum lesions
located in surface epithelial cells, villi structure and/or crypt gland
cells were scored as ‘‘1’’ for each of them. The sum of all three
scores was computed as being a toxicity grade, theoretically
ranging from 0 (normal) to 3 (alteration in each item).
Statistical analyses
Means and SEM were calculated for each studied variable.
Differences of mRNA expression of abcc2 according to ZT, genetic
background and sex were validated using multiple-way analyses of
variance (ANOVA). The statistical significance of a sinusoidal 24 h
rhythm was further documented by Cosinor [22]. This method
further computed the parameters of the best-fitting 24-h cosine
function with their 95% confidence limits, i.e. mesor (mean),
amplitude (half the extent of variation) and acrophase (time of
maximum, referred to ZT0). Intergroup differences in protein
expression and ileum lesion scores were statistically validated by
multiple-way ANOVA. Incidence data were compared by x
2 test.
Rhythm parameter comparison tests involved Hotelling t-test [23].
All statistical tests were two-sided and performed using SPSS v.16
for Windows software (Paris-La De ´fense, France).
Results
Focal and circadian mRNA expression in ileum of male
B6D2F1
Mean mRNA expression of abcc2 in ileum mucosa varied three-
fold over the 24 h in male B6D2F1 mice, according to results from
Study 1. Highest values were found in the first half of the dark
span, with a peak at ZT12, while the nadir occurred at ZT0
(ANOVA, p=0.02) (Figure 1). A sinusoidal pattern in abcc2
expression was further confirmed with cosinor (p=0.0011). The
circadian amplitude was 55% of the mesor (95% Confidence
Limits, CL: 30 to 80), and the acrophase was located at ZT13:35
(11:50 to 15:25). Conversely, there was barely any mRNA
expression in ileum serosa (Figure 1), without any significant
rhythm detection (cosinor, p=0.07).
Relevance of strain and gender for the circadian
expression of abcc2 transcription in ileum mucosa
In study 2, mean mRNA expression of abcc2 also varied six-fold
over the 24 h, with a peak at ZT12 and a nadir at ZT0 in male
B6D2F1 (ANOVA, p=0.04) (Figure 2A), Cosinor analysis further
confirmed a sinusoidal pattern (p=0.0023). The circadian
amplitude was 72% of the mesor (35 to 110), and the acrophase
was localized at ZT10:20 (8:20 to 12:25). Thus, both studies 1 and
2 demonstrated a circadian rhythm with similar characteristics for
the abcc2 mRNA expression in the ileum mucosa of male B6D2F1
mice.
The mRNA expression of abcc2 also displayed a statistically
significant six-fold variation over the 24 h in the ileum mucosa of
female B6D2F1 (ANOVA, p=0.008). While the nadir occurred at
ZT0, the peak time was located at ZT9 (Figure 2A). The circadian
amplitude was 70% of the mesor (33 to 106) and the acrophase
occurred at ZT 9:30 (7:25 to 11:40) as estimated by cosinor
(p=0.0023).
Similar three- to four-fold circadian variations were found in
male and female B6CBAF1, with highest values occurring from
ZT9 to ZT15, and a trough at ZT0 (Figure 2B) (ANOVA,
p=0.004 in male; p=0.003 in female). The sinusoidal pattern of
these rhythms was confirmed by cosinor for mice of each sex
(p=0.00026 and p=0.00012, respectively). The circadian param-
eters were similar in males and females, with respective relative
amplitude of 68% of the mesor [38 to 98] and 51% [30 to 73] –
and respective acrophases occurring at ZT11:40 (9:55 to 13:20)
and ZT11:50 (10:05 to 13:30). Three-way ANOVA of all the
mRNA expression data of abcc2 revealed statistically significant
differences as a function of circadian time (p,0.001) and genetic
background (p,0.001), but not sex (p=0.106). However, the
comparison of circadian acrophases showed statistically significant
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not between males and females B6CBAF1 (p=0.77).
Relevance of strain and sex for the circadian expression
of abcc2 protein in ileum mucosa (Study-3)
Abcc2 protein was mostly expressed in the plasma membrane
and occasionally in the nuclear membrane of the cells in ileum
mucosa, as showed by abcc2 co-localization with a known plasma
membrane marker, likebcatenin (Figure 3A). The spatial distribu-
tion patterns were similar whatever the sex or the strain (Figures 4A
and 4B). Protein expression was barely detectable in the colon, so
that no quantification was attempted. The expression of abcc2
protein displayed consistent 24 h changes in male and female
B6D2F1, as well as in male and female B6CBAF1, with apparent
strain- and/or sex-dependent differences. Protein expression
peaked at ZT12 both in male and female B6D2F1 while it was
lowest at ZT15 in males and at ZT15, ZT0 and ZT3 in females
(Figure 4C). The extent of circadian variation was ,three-fold in
males and ,two-fold in females. In B6CBAF1, abcc2 protein
expression was highest from ZT12 to ZT15 in males and at ZT12
in females. Lowest values were found at ZT0 in males and at ZT15
in females (Figure 4D). The range of change was ,two fold in
female mice and much weaker in males. Three-way ANOVA
validated statistically significant differences as a function of ZT
(p,0.001) and strain (p=0.048), but not sex (p=0.07). Further-
more, statistically significant interactions were found between ZT
and strain (p=0.001), and between ZT and sex (p=0.035) as well
as all three factors (p=0.004. Overall, mean protein expression
was correlated with mean mRNA expression in each group at each
ZT (r=0.52; p,0.05).
Relevance of strain and sex for ileum chronotolerance for
irinotecan (Study-4)
Histologic lesions in ileum were found in mice from each strain
and sex, with scores up to two (Figure 5A). Ileum mucosa was
mostly damaged two days after treatment completion, with full
recovery within four days in all groups. Irinotecan timing
determined the incidence of mice free of ileum lesions (grade 0)
as well as the average lesion score. Thus no ileum damage was
observed in 46.4% of the mice receiving irinotecan at the ZT
predicted to achieve best tolerability as compared to 11.5% of
those treated at the ZT predicted to yield poorest tolerability (13/
28 vs. 3/26; p fromx
2=0.00003) (Figure 5B). The respective mean
scores were 0.6460.11 and 1.0060.01 for the respective ‘‘best’’
and ‘‘worst’’ times (p from ANOVA=0.016) (Figure 5C).
The incidence of mice without any ileum damage was ,twice as
high in male as compared to female mice, irrespective of strain (5/
26, 19.2% vs 9/28, 32%; p from x
2=0.05), and in B6CBAF1 as
compared to B6D2F1 (10/27, 37% vs 4/27, 14.8%; p from
x
2=0.0006). Three-way ANOVA further confirmed the relevance
of ‘‘best’’ vs. ‘‘worst’’ circadian timing (p=0.018), with possible
effects of strain (p=0.06) and timing*sex interaction (p=0.07).
Thus, Figure 5D illustrates that circadian timing played a
prominent role for ileum tolerability in all groups except male
B6D2F1.
Discussion
The current study is first to demonstrate that abcc2/abcc2
expression is strongly regulated along the 24 h in mouse ileum
mucosa. The magnitude of the circadian changes ranged from 3-
to 6-fold for mRNA expression and from 2- to 3-fold for protein
expression. Accordingly, the ileum tolerability of irinotecan, an
anticancer drug whose cellular efflux involves abcc2, was
improved nearly fourfold with drug dosing near the time of
maximum abcc2/abcc2 expressions.
The multiple circadian controls of drug absorption, distribution,
metabolism, elimination and toxicity (ADMET) partly account for
dosing time dependencies in the pharmacokinetics and toxic
effects of medications [3,6]. Indeed, circadian changes were shown
for irinotecan disposition and tolerability in mice [14,15]. Limited
human data suggested that this was also the case in cancer patients
[6]. Circadian clocks control the transcription of some ABC family
members, including abcc2 (mrp2) in mouse liver [18,24] and
intestine [19,25,26]. Since irinotecan efflux is actively mediated by
abcc2, and this gene is highly expressed in ileum mucosa, we
hypothesized that abcc2 rhythms in ileum would participate in
small intestine chronotolerance for irinotecan [15].
Figure 1. Circadian patterns of abcc2 mRNA expression in the ileum of male B6D2F1 mice. Mean (6 SEM) in mucosa and in serosa as a
function of Zeitgeber Time (ZT), with ZT0 as light onset. Statistically significant differences according to ZT were validated for mucosa with ANOVA
(p=0.02). A statistically significant 24 h rhythm was confirmed for mucosa with cosinor (p=0.0011).
doi:10.1371/journal.pone.0020393.g001
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Mean (6 SEM) as a function of Zeitgeber Time (ZT), with ZT0 as light onset. (A) male and female B6D2F1; (B) male and female B6CBAF1. Mean abcc2
expression increased six-fold from ZT0 (trough) to ZT12 (peak) for B6D2F1 males and ZT0 (trough) to ZT9 (peak) for B6D2F1 females (ANOVA, p=0.04;
Cosinor, p=0.0023 for B6D2F1 males and ANOVA, p=0.0008; Cosinor, p=0.0023 for B6D2F1 females). Similar three- to four-fold circadian variations
were found in male and female B6CBAF1, with highest values occurring from ZT9 to ZT15, and a trough at ZT0 (ANOVA, p=0.004 in male; p=0.003 in
female). The rhythm was validated by cosinor for B6CBAF1 (p=0.00026 and p=0.00012 in male and female, respectively).
doi:10.1371/journal.pone.0020393.g002
Figure 3. Co-localization of abcc2 and b-catenin in the membrane of ileum mucosa cells. Double immunofluorescence staining of abcc2
(green) and b-catenin (red) in mouse ileum using confocal laser scanning microscopy. Far-red fluorescent DNA dye DRAQ5 (blue) for visualizing
nuclei. Co-localization between abcc2 and b-catenin was shown as yellow. A) Original magnification 406(scale bar, 20 mm). B) Higher magnification
of selected area.
doi:10.1371/journal.pone.0020393.g003
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serosa as shown in this study, as well as in colon mucosa [9,10]. On
the contrary, both mRNA and protein expressions of abcc2 were
high and rhythmic in the apical region of the small intestine, where
the efflux function of abcc2 involves substrate carrier from apical to
basolateral side [7]. While the organ specificity of clock-controlled
genes was previously shown [27–29], our study further emphasized
that rhythmic gene expressions could also depend upon the
functional role of a specific area within a given organ. This implies
that a better knowledge of the functional relevance of circadian
rhythms should stem from careful examination of different regions
in the same organ. The circadian amplitudes of the mRNA
expression of abcc2 or other ABC transporters in mouse or rat small
intestine were low in the studies involving total ileum segment and
large in that of ileum mucosa [19,26,30]. Maximum expression in
total jejunum was reported to occur at ZT8in male C57BL/6J mice
and at ZT12 in male Sprague-Dawley rats [19,30] i.e. in the second
half of the rest span of these nocturnally-active rodents.
The rhythmic patterns in abcc2 expression were similar in male
and female B6CBAF1, while they differed between male and
Figure 4. Confocal immunohistochemistry imaging of abcc2 protein expression in mouse ileum, according to circadian time,
genetic background and sex. A) Selected examples in male (upper row) and female (lower row) B6D2F1.B )Id in B6CBAF1. C) Histogram depicting
the changes in mean (6SEM) protein expression at four ZTs associated with low or high mRNA expressions in male and female B6D2F1.D )Id in
B6CBAF1. NOTE: Three-way ANOVA confirmed statistically significant differences as a function of ZT (p,0.001), strain (p=0.048). Statistically
significant interactions were detected between ZT*strain (p=0.001), ZT*sex (p=0.035) and ZT*strain*sex (p=0.004).
doi:10.1371/journal.pone.0020393.g004
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20393Figure 5. Tolerance of mouse small intestine for irinotecan, as a function of circadian timing, genetic background and sex. According
to previous studies, the circadian timing (as ZT) corresponding to best tolerability of irinotecan was ZT11 in male B6D2F1 and ZT15 in female B6D2F1
as well as in male or female B6CBAF1 mice. The worst tolerability resulted from irinotecan dosing at ZT23 in male B6D2F1, ZT3 in female B6D2F1, and
ZT7 in male or female B6CBAF1. Transverse sections of ileum 2 days after the fourth daily dose of irinotecan (50 mg/kg/d64 days). Hemalun-
erythrosine-safran staining. A, control, Grade 0; B, Grade 1; C, Grade 2. Bar graph of the proportion (6SEM) of mice free of ileum lesions (Grade 0)
according to circadian timing of irinotecan (x
2, p=0.00003). Bar graph of the proportion (6 SEM) of toxicity grade according to circadian timing of
irinotecan (ANOVA, p=0.016). (D) Histogram of mean (6 SEM) grade of ileum toxicity according to circadian timing, genetic background.and sex. The
incidence of mice without any ileum damage was significantly higher in male as compared to female mice, irrespective of strain (x
2, p=0.05), and in
B6CBAF1 as compared to B6D2F1 (x
2, p=0.0006). Three-way ANOVA validated the relevance of ‘‘best’’ vs. ‘‘worst’’ circadian timing (p=0.018).
doi:10.1371/journal.pone.0020393.g005
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addition, mean abcc2 expression was nearly doubled in B6CBAF1,
as compared to B6D2F1. Thus, strain- and sex- related differences
characterized the circadian mRNA expression of abcc2. They were
confirmed for the protein expression of this gene, at four selected
ZT, located near maximum and minimum mRNA expressions.
While both mRNA and protein expressions peaked near ZT12 in
male and female mice from either strain, the temporal patterns
varied largely as a function of genetic background and sex.
Consistently with the mRNA data, mean protein expression was
also highest in B6CBAF1 as compared to B6D2F1.
Irinotecan damaged ileum mucosa over the two days following
treatment completion, while full recovery was noticed two days
later, in good agreement with prior report [15]. The tolerability of
mouse ileum mucosa for irinotecan was largely improved following
drug administration at ZT11 or ZT15, pending upon genetic
background and sex. Furthermore, overall tolerability was best in
male mice, and in B6CBAF1.
Thus, the maxima in circadian mRNA and protein expressions
of abcc2 in ileum mucosa occurred near ZT12, when irinotecan
tolerance was best in pooled groups of mice. However, wrongly
timed irinotecan produced less ileum toxicity in male B6D2F1 than
in male B6CBAF1 or in females from any strain. Irinotecan also
damaged other target tissues such as colon and bone marrow.
Lesions in colon mucosa were prominent in male but not in female
B6D2F1 mice. The main toxicity in female B6D2F1 was
hematologic rather than colic [31]. Multiple mechanisms are
involved in irinotecan chronotolerance at many tissue levels,
including liver, ileum and colon mucosa as well as bone marrow,
with strain and sex dependencies. This was shown for liver mRNA
expressions of ces2, ugt1a1 and top1, three enzymes respectively
involved into the bioactivation of irinotecan, its detoxification and
its molecular toxicity [16]. Current and previous data support
highest detoxification - high ileum abcc2 and liver ugt1a1 mRNA
and protein expressions – and lowest bioactivation and target
availability- low expressions of ces2 and top1, respectively in
B6CBAF1 as compare to B6D2F1. Indeed, ileum toxicity was least
in B6CBAF1 as compared to B6D2F1. These results at tissue
toxicity level were consistent with those earlier found for body
weight loss [16]. As a consequence, the relevance of the circadian
pattern in abcc2 mRNA and protein expressions in ileum has to be
interpreted against the several other determinants of irinotecan
chronotolerance such as ugt1a1, ces2, top1 rhythms in different
tissues.
In aggregate, our study shows that the local circadian control of
ABCC2/abcc2-mediated detoxification strongly depends upon
tissue location, genetic background and sex. This detoxification
rhythm can importantly contribute to host tolerability for
irinotecan and probably other anticancer drugs such as topotecan,
cisplatin, docetaxel, doxorubicin, epirubicin, methotrexate, pacli-
taxel, and vinblastine whose efflux involves abcc2 [7]. Interest-
ingly, a circadian rhythm has been shown for the tolerability of
each of these agents in mice or rats [6]. However, several
mechanisms jointly account for the chronopharmacology of
anticancer drugs at cellular, tissue and whole organism level. This
statement calls for the integration of our finding into a
comprehensive systems biology approach to cancer chronother-
apeutics [32–34]. The challenge is to identify the theoretically
optimal chronotherapeutic schedules that will best spare healthy
tissues from toxic insults in an individual patient.
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